Humacyte (NASDAQ:HUMA) Sees Strong Trading Volume

Humacyte, Inc. (NASDAQ:HUMA) saw unusually-strong trading volume on Tuesday . Approximately 638,996 shares were traded during trading, a decline of 64% from the previous session’s volume of 1,775,598 shares.The stock last traded at $5.32 and had previously closed at $5.37.

Analyst Upgrades and Downgrades

HUMA has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Humacyte in a report on Tuesday. Benchmark reaffirmed a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Tuesday. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price on shares of Humacyte in a report on Tuesday, March 26th.

Humacyte Stock Up 11.0 %

The stock’s fifty day moving average price is $5.98 and its 200 day moving average price is $4.23. The stock has a market cap of $675.18 million, a P/E ratio of -5.67 and a beta of 1.52. The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). As a group, research analysts forecast that Humacyte, Inc. will post -0.95 earnings per share for the current fiscal year.

Insider Transactions at Humacyte

In related news, Director Gordon M. Binder purchased 50,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were purchased at an average price of $6.78 per share, with a total value of $339,000.00. Following the acquisition, the director now directly owns 160,000 shares of the company’s stock, valued at $1,084,800. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Brady W. Dougan sold 271,518 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the transaction, the director now owns 4,559,140 shares of the company’s stock, valued at approximately $33,281,722. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gordon M. Binder bought 50,000 shares of Humacyte stock in a transaction that occurred on Wednesday, May 15th. The shares were acquired at an average cost of $6.78 per share, for a total transaction of $339,000.00. Following the acquisition, the director now owns 160,000 shares in the company, valued at approximately $1,084,800. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 54,412 shares of company stock valued at $369,107 and have sold 1,628,820 shares valued at $12,464,121. Insiders own 23.10% of the company’s stock.

Hedge Funds Weigh In On Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in HUMA. GSA Capital Partners LLP grew its holdings in shares of Humacyte by 139.5% during the 3rd quarter. GSA Capital Partners LLP now owns 355,918 shares of the company’s stock valued at $1,043,000 after purchasing an additional 207,333 shares during the last quarter. Whittier Trust Co. of Nevada Inc. purchased a new stake in Humacyte during the 4th quarter valued at $28,000. SG Americas Securities LLC boosted its position in Humacyte by 52.8% during the 4th quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock valued at $46,000 after buying an additional 5,645 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Humacyte by 350.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $34,000 after buying an additional 9,325 shares during the period. Finally, United Asset Strategies Inc. boosted its position in Humacyte by 53.9% during the 4th quarter. United Asset Strategies Inc. now owns 221,308 shares of the company’s stock valued at $629,000 after buying an additional 77,500 shares during the period. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.